AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and COVID-19 through PREPAiRE, an AI powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing.
利乐生物制药公司。(场外交易代码：TBPMF)(多伦多证券交易所代码：TBP)(法兰克福证券交易所股票代码：JAM1)，宣布Onternabz的研究结果 与法比拉韦联合应用针对ARDS(急性呼吸窘迫综合征)、脓毒症和新冠肺炎做好准备，一个艾动力平台，有目的地集成目标识别、验证、线索发现优化、药物合成和临床前测试。
Results from the study demonstrate that Tetra's investigational therapeutic, ARDS-003, which contains the active pharmaceutical ingredient Onternabez, acts against various ARDS and sepsis targets, such as IL-6 and IL-8. Onternabez plays an important role in mitigating the inflammatory response in various targets of inflammatory conditions.
研究结果表明，利乐的研究治疗药物ARDS-003含有有效的药物成分Onternabez，可对抗各种ARDS和脓毒症靶点，如IL-6和IL-8。恩替那贝兹在减轻炎症条件下不同靶点的炎症反应方面起着重要作用。
Favipiravir acts against different SARS-CoV-2 targets, such as spike glycoprotein and nucleoprotein. The interaction between Favipiravir and Onternabez against SARS-COV-2 yields a positive molecule synergy probability which is considered significant and justifies the combination of the two drugs to create a new therapeutic that is expected to be beneficial to increase treatment efficacy and reduce the duration of disease. Favipiravir can control the source of infection. Onternabez would contribute to the antiviral efficacy and can control the result of infection (i.e., the inflammatory response).
法韦拉韦针对SARS-CoV-2的不同靶点发挥作用，如刺激性糖蛋白和核蛋白。Favipiravir和Onternabz之间针对SARS-COV-2病毒的相互作用产生了一个积极的分子协同概率，这被认为是重要的，并证明将这两种药物结合起来创造一种新的治疗方法是合理的，预计将有利于提高治疗效率和缩短病程。法维拉韦可以控制感染源。恩替那贝兹有助于抗病毒疗效，并可以控制感染的结果(即炎症反应)。
Dr. Guy Chamberland, CEO and chief regulatory officer at Tetra stated "We are very pleased by these artificial intelligence results as well as the recent positive results from the PIONEER trial. This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases. We are more excited than ever about our collaboration with Cellvera and the possibility of delivering the next scientific breakthroughs."
盖伊·钱伯兰博士利乐首席执行官兼首席监管官表示：“我们对这些人工智能的结果以及最近先锋试验的积极结果感到非常高兴。这突显了我们对Cellvera开发一种创新的候选组合药物来对抗病毒疾病。我们比以往任何时候都对我们与Cellvera的合作以及实现下一步科学突破的可能性感到兴奋。“
Cannabinoids and COVID-19
大麻素和新冠肺炎
According to IUPHAR/BPS Guide to pharmacology, Onternabez is a form of synthetic cannabinoid, which acts as a CB2 receptor agonist and has anti-inflammatory activity. Recent research has shown that natural cannabinoids can be effective against COVID-19 too. Cannabinoid acids in hemp - cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA have the ability to bind to the SARS-CoV-2 spike protein – the virus that causes COVID-19. By binding to the spike protein, these acids can block the virus from reaching into cells and causing infection.
根据IUPHAR/BPS药理学指南，Onternabiz是一种合成大麻素，其作用是CB2受体激动剂，具有抗炎活性。最近的研究表明，天然大麻素也可以有效地对抗新冠肺炎。大麻中的大麻酸-大麻酚酸和大麻二酚酸，也被称为CBDA-能够与导致新冠肺炎的病毒SARS-CoV-2刺突蛋白结合。通过与刺突蛋白结合，这些酸可以阻止病毒进入细胞并导致感染。
Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.
获取您的每日大麻用量新闻 在本辛加大麻上。不要错过对该行业任何重要发展的期望。
Photo: Courtesy of CNW Group/Tetra Bio-Pharma Inc.
图片来源：CNW集团/利乐生物制药公司。
Related News
相关新闻
Tetra Bio-Pharma Announces Second Closing Of Financing With Alpha Blue Ocean
利乐生物制药公司宣布与阿尔法蓝海公司第二次完成融资
Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
利乐与赛尔维拉合作开发新冠肺炎的口服疗法
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
临床前试验结果证实靶向2型大麻素受体有助于缓解脓毒症相关疾病
译文内容由第三方软件翻译。